



MethylScan®: Affinity Enrichment and Mass Spectrometry Analysis of Protein Methylation

Hongbo Gu, Ailan Guo, Jing Zhou, Daniel Mulhern, Yi Wang, Kimberly Lee, Vicky Yang, Mike Aguiar, Jon Kornhauser, Xiaoying Jia, Jian-Min Ren, Sean Beausoleil, Jeffrey Silva • Cell Signaling Technology, Danvers, MA

Introduction

Protein methylation is a post-translational modification that predominantly occurs on arginine and lysine residues. Arginine methylation is catalyzed by protein arginine methyltransferase (PRMT) that can be categorized into two major groups which are both capable of catalyzing the formation of monomethyl arginine (MMA). Type I PRMT is specifically responsible for adding a second methyl group to the same guanidino nitrogen atom of arginine to form asymmetric dimethylarginine (aDMA). Type II PRMT catalyzes the reaction of adding the second methyl group to a different guanidino nitrogen atom to form symmetric dimethylarginine (sDMA) [Fig. 1]. Many substrates identified for PRMTs are cytoplasmic and nuclear proteins indicating the potential roles of arginine methylation in RNA processing, transcriptional regulation, DNA damage repairs.

The methylation reaction of sequentially adding three methyl groups to lysine residues forming mono-methyl (K-Me), di-methyl (K-2Me) and tri-methyl (K-3Me) lysine are carried out by the protein lysine methyltransferases (PKMTs) enzyme family [Fig. 1]. Lysine methylation is best known for modifying residues of histone proteins, regulating chromatin compaction and gene transcription.




Figure 1: Chemistry of arginine and lysine methylation.

To achieve the quantitative analysis of protein methylation, we have developed a novel technology called MethylScan® utilizing immuno-affinity enrichment at the peptide level using a series of specific monoclonal antibodies against all types of protein methylation followed by LC-MS/MS analysis (IAP-MS). Facilitated by specific enrichment and high-throughput analysis by mass spectrometry, we have identified a large number of novel methylation sites on arginine and lysine from HCT116 cells; we also conducted a binary comparison of arginine methylation in mouse brain and embryo using MethylScan to reveal the quantitative change of over 1,000 sites of arginine methylation in fetal and adult tissues.

METHODS

CELL TREATMENT AND WESTERN BLOTS

HCT116 cells were cultured in DMEM medium with 10% FBS and treated with 20uM of AdOx for 24 hours, followed by another treatment of 20 uM of AdOx in new medium. Cells were lysed by a buffer containing 1% Triton X-100, protease and phosphatase inhibitors. Equal amounts of cleared cell lysate were loaded into SDS-PAGE and transferred to nitrocellulose membrane for western blots using specific methylation antibodies.

QUALITATIVE IDENTIFICATION OF METHYLATION SITES

Subconfluent HCT116 cells were harvest and lysed in 9M urea buffer containing phosphatase inhibitors. A general procedure for generating lyophilized tryptic peptides from whole cell lysates can be found in Stokes et al., 2012. Enrichment of methylated peptides was achieved by immuno-precipitation using a corresponding methyl antibody (250ug) from 10mg of tryptic peptides. Enriched peptides were analyzed by LC-MS/MS over a linear gradient of 72 min. MS/MS spectra were collected in data-dependent mode with a Q-Exactive mass spectrometer. Raw data was searched against the NCBI human database and identified methylated peptides were filtered using a 5% FDR.

RESULTS




Figure 2: Methyl-Arginine antibodies show good specificities.

R-Me antibody signal can be blocked by antigen peptide but not the control peptide without a methyl group. R-a2Me signal can be blocked by antigen peptide with asymmetric di-methyl or arginine but not the control peptide with symmetric di-methyl on arginine.




Figure 3: Statistical Summary of Sites, Peptides and Proteins with Methylation Identified by MethylScan from HCT116 Cells.

A 5% FDR was applied to filter the SORCERER results.





Figure 4: Motif Analysis and Functional Distribution of Arginine Methylation Identified in HCT-116 Cell. Both clones of R-Me antibodies (D5A12 and Me-R4-100) and R-a2Me antibody prefer binding methylated peptides with glycine enriched motif. Functional analysis shows methylations are abundantly involved in the regulation of transcription and RNA binding/processing.




Figure 5: MS/MS spectrum of mono-methylation on K736 of Histone-lysine N-methyltransferase (EZH1).

The presence of both b and y ions flanking the modification site confidently localized the position of the methylation (highlighted in red and blue text).




Figure 6: Quantification of mono-methylated peptides from mouse brain and embryo. (A) Different patterns of overexpression of arginine mono-methylation and asymmetric dimethylation were observed by western blots using corresponding antibodies; (B) Scheme of quantification of relative abundance of methyl-peptides by in-house label free quantitation algorithm (LFQ); peptide sequence were identified by searching the raw MS/MS spectra against NCBI mus musculus database; filtered searching results containing arginine-methylation peptides were used for generating extracted ion chromatograms (EICs) from raw files; relative abundance ratio of particular arginine methylation between mouse brain and embryo was calculated using either peak height or peak area of the corresponding EICs.

Fold Change	Protein Name	Site	Accession	Peptide
Brain/Embryo	PRMT1	1970_1974	Q53303	YKQKQK
Brain/Embryo	PRMT2	1088_1170	Q53307	YKQKQK
Brain/Embryo	PRMT4	1346_1348	Q53305	YKQKQK
Brain/Embryo	PRMT5	1346_1348	Q53306	YKQKQK
Brain/Embryo	PRMT6	1346_1348	Q53308	YKQKQK
Brain/Embryo	PRMT7	1346_1348	Q53309	YKQKQK
Brain/Embryo	PRMT8	1346_1348	Q53310	YKQKQK
Brain/Embryo	PRMT9	1346_1348	Q53311	YKQKQK
Brain/Embryo	PRMT10	1346_1348	Q53312	YKQKQK
Brain/Embryo	PRMT11	1346_1348	Q53313	YKQKQK
Brain/Embryo	PRMT12	1346_1348	Q53314	YKQKQK
Brain/Embryo	PRMT13	1346_1348	Q53315	YKQKQK
Brain/Embryo	PRMT14	1346_1348	Q53316	YKQKQK
Brain/Embryo	PRMT15	1346_1348	Q53317	YKQKQK
Brain/Embryo	PRMT16	1346_1348	Q53318	YKQKQK
Brain/Embryo	PRMT17	1346_1348	Q53319	YKQKQK
Brain/Embryo	PRMT18	1346_1348	Q53320	YKQKQK
Brain/Embryo	PRMT19	1346_1348	Q53321	YKQKQK
Brain/Embryo	PRMT20	1346_1348	Q53322	YKQKQK
Brain/Embryo	PRMT21	1346_1348	Q53323	YKQKQK
Brain/Embryo	PRMT22	1346_1348	Q53324	YKQKQK
Brain/Embryo	PRMT23	1346_1348	Q53325	YKQKQK
Brain/Embryo	PRMT24	1346_1348	Q53326	YKQKQK
Brain/Embryo	PRMT25	1346_1348	Q53327	YKQKQK
Brain/Embryo	PRMT26	1346_1348	Q53328	YKQKQK
Brain/Embryo	PRMT27	1346_1348	Q53329	YKQKQK
Brain/Embryo	PRMT28	1346_1348	Q53330	YKQKQK
Brain/Embryo	PRMT29	1346_1348	Q53331	YKQKQK
Brain/Embryo	PRMT30	1346_1348	Q53332	YKQKQK
Brain/Embryo	PRMT31	1346_1348	Q53333	YKQKQK
Brain/Embryo	PRMT32	1346_1348	Q53334	YKQKQK
Brain/Embryo	PRMT33	1346_1348	Q53335	YKQKQK
Brain/Embryo	PRMT34	1346_1348	Q53336	YKQKQK
Brain/Embryo	PRMT35	1346_1348	Q53337	YKQKQK
Brain/Embryo	PRMT36	1346_1348	Q53338	YKQKQK
Brain/Embryo	PRMT37	1346_1348	Q53339	YKQKQK
Brain/Embryo	PRMT38	1346_1348	Q53340	YKQKQK
Brain/Embryo	PRMT39	1346_1348	Q53341	YKQKQK
Brain/Embryo	PRMT40	1346_1348	Q53342	YKQKQK
Brain/Embryo	PRMT41	1346_1348	Q53343	YKQKQK
Brain/Embryo	PRMT42	1346_1348	Q53344	YKQKQK
Brain/Embryo	PRMT43	1346_1348	Q53345	YKQKQK
Brain/Embryo	PRMT44	1346_1348	Q53346	YKQKQK
Brain/Embryo	PRMT45	1346_1348	Q53347	YKQKQK
Brain/Embryo	PRMT46	1346_1348	Q53348	YKQKQK
Brain/Embryo	PRMT47	1346_1348	Q53349	YKQKQK
Brain/Embryo	PRMT48	1346_1348	Q53350	YKQKQK
Brain/Embryo	PRMT49	1346_1348	Q53351	YKQKQK
Brain/Embryo	PRMT50	1346_1348	Q53352	YKQKQK
Brain/Embryo	PRMT51	1346_1348	Q53353	YKQKQK
Brain/Embryo	PRMT52	1346_1348	Q53354	YKQKQK
Brain/Embryo	PRMT53	1346_1348	Q53355	YKQKQK
Brain/Embryo	PRMT54	1346_1348	Q53356	YKQKQK
Brain/Embryo	PRMT55	1346_1348	Q53357	YKQKQK
Brain/Embryo	PRMT56	1346_1348	Q53358	YKQKQK
Brain/Embryo	PRMT57	1346_1348	Q53359	YKQKQK
Brain/Embryo	PRMT58	1346_1348	Q53360	YKQKQK
Brain/Embryo	PRMT59	1346_1348	Q53361	YKQKQK
Brain/Embryo	PRMT60	1346_1348	Q53362	YKQKQK
Brain/Embryo	PRMT61	1346_1348	Q53363	YKQKQK
Brain/Embryo	PRMT62	1346_1348	Q53364	YKQKQK
Brain/Embryo	PRMT63	1346_1348	Q53365	YKQKQK
Brain/Embryo	PRMT64	1346_1348	Q53366	YKQKQK
Brain/Embryo	PRMT65	1346_1348	Q53367	YKQKQK
Brain/Embryo	PRMT66	1346_1348	Q53368	YKQKQK
Brain/Embryo	PRMT67	1346_1348	Q53369	YKQKQK
Brain/Embryo	PRMT68	1346_1348	Q53370	YKQKQK
Brain/Embryo	PRMT69	1346_1348	Q53371	YKQKQK
Brain/Embryo	PRMT70	1346_1348	Q53372	YKQKQK
Brain/Embryo	PRMT71	1346_1348	Q53373	YKQKQK
Brain/Embryo	PRMT72	1346_1348	Q53374	YKQKQK
Brain/Embryo	PRMT73	1346_1348	Q53375	YKQKQK
Brain/Embryo	PRMT74	1346_1348	Q53376	YKQKQK
Brain/Embryo	PRMT75	1346_1348	Q53377	YKQKQK
Brain/Embryo	PRMT76	1346_1348	Q53378	YKQKQK
Brain/Embryo	PRMT77	1346_1348	Q53379	YKQKQK
Brain/Embryo	PRMT78	1346_1348	Q53380	YKQKQK
Brain/Embryo	PRMT79	1346_1348	Q53381	YKQKQK
Brain/Embryo	PRMT80	1346_1348	Q53382	YKQKQK
Brain/Embryo	PRMT81	1346_1348	Q53383	YKQKQK
Brain/Embryo	PRMT82	1346_1348	Q53384	YKQKQK
Brain/Embryo	PRMT83	1346_1348	Q53385	YKQKQK
Brain/Embryo	PRMT84	1346_1348	Q53386	YKQKQK
Brain/Embryo	PRMT85	1346_1348	Q53387	YKQKQK
Brain/Embryo	PRMT86	1346_1348	Q53388	YKQKQK
Brain/Embryo	PRMT87	1346_1348	Q53389	YKQKQK
Brain/Embryo	PRMT88	1346_1348	Q53390	YKQKQK
Brain/Embryo	PRMT89	1346_1348	Q53391	YKQKQK
Brain/Embryo	PRMT90	1346_1348	Q53392	YKQKQK
Brain/Embryo	PRMT91	1346_1348	Q53393	YKQKQK
Brain/Embryo	PRMT92	1346_1348	Q53394	YKQKQK
Brain/Embryo	PRMT93	1346_1348	Q53395	YKQKQK
Brain/Embryo	PRMT94	1346_1348	Q53396	YKQKQK
Brain/Embryo	PRMT95	1346_1348	Q53397	YKQKQK
Brain/Embryo	PRMT96	1346_1348	Q53398	YKQKQK
Brain/Embryo	PRMT97	1346_1348	Q53399	YKQKQK
Brain/Embryo	PRMT98	1346_1348	Q53400	YKQKQK
Brain/Embryo	PRMT99	1346_1348	Q53401	YKQKQK
Brain/Embryo	PRMT100	1346_1348	Q53402	YKQKQK

Table 1: Representative arginine-methylation peptides from quantitative analysis. Fold change for each methylation site is calculated by converting the ratio of peptide ion abundance from brain and embryo. "Brain" and "Embryo" in the fold change column indicate the methylation specifically existed in the tissue. The full table of quantitative analysis can be downloaded from www.cellsignal.com/services/methylation.html.




Figure 7: Scatter plot showing the log2 ratio of the abundance of the arginine-methylated peptides quantified from brain and embryo Top region in green and bottom region in red are the peptides that are abundantly rich in brain and embryo, respectively. Tissue specific methylated peptides are assigned with the log2 ratio of 15 and -15 for brain and embryo.




Figure 8: Bioinformatic analysis of interactions between proteins with arginine methylation specifically enriched in mouse brain (A) and embryo (B).

Summary

• A panel of monoclonal antibodies for protein methylation with high specificity was developed and validated.
• A robust method for qualifying methylation by antibody affinity enrichment and Lc-MS/MS was established.

References

1. Zhang Y. et al. (2001) *Genes Dev.* 15: 2343–2360.
2. Stokes M. et al. (2012) *Mol. Cell Proteomics* 11:187–201.

Contact Information

Hongbo Gu
Cell Signaling Technology, Inc.
Tel: 978-867-2300 (x2211)
Email: hgu@cellsignal.com

PTMScan® Services Department
Email: ptmscan@cellsignal.com
Visit www.cellsignal.com/services/index.html
for more information regarding MethylScan